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Should liver enzymes 
be checked in a patient
taking niacin?
■ EVIDENCE-BASED ANSWER
No randomized trials directly address the question
of frequency of liver enzyme monitoring with
niacin use. Niacin use is associated with early and
late hepatotoxicity (strength of recommendation
[SOR]: B, based on incidence data from random-
ized controlled trials and systematic reviews of
cohort studies). Long-acting forms of niacin 
(Slo-Niacin) are more frequently associated 
with hepatotoxicity than the immediate-release
(Niacor, Nicolar) or extended-release (Niaspan)
forms (SOR: B, based on 1 randomized controlled
trial and systematic reviews of cohort studies). 
The combination of statins and niacin at usual
doses does not increase the risk of hepatotoxicity
(SOR: A, based on randomized controlled trials).
Screening has been recommended at baseline, 6 to
8 weeks after reaching a daily dose of 1500 mg, 6
to 8 weeks after reaching the maximum daily dose,
then annually (SOR: C, based on expert opinion).
■ EVIDENCE SUMMARY
Three forms of niacin exist: immediate-release
(IR), sustained-release/long-acting (SR/LA), and
extended-release (ER), which is currently avail-
able only as Niaspan.1 Published incidence of
niacin-induced hepatotoxicity varies according to
the definition of hepatotoxicity, with a 0% to 46%
rate of elevated hepatic enzymes. Hepatotoxicity
includes mild liver enzyme elevations, steatosis,
hepatitis, abnormal liver biopsies, or fulminant
hepatic failure.2,3 Between 1982 and 1992, 11
case reports have linked IR nicotinic acid to a
wide range of hepatotoxicities. For patients tak-
ing LA/SR niacin doses >3 g/d or switching from
the IR to the LA product, 21 case reports have
linked LA/SR niacin with adverse outcomes.3,4 In
several of the LA/SR cases, patients were rechal-
lenged with IR formulations with no recurrent
hepatocellular damage.3,4 In these case reports,
onset of hepatotoxicity ranged from 2 days to 18
months. In a retrospective cohort of 969 veterans
taking LA/SR niacin, those who developed hepa-
totoxicity had onset between 1 and 28 months of
initiating treatment.2 Studies evaluating the risk
of hepatotoxicity with niacin alone and in combi-
nation with statins are summarized in the Table.
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form, the dosage be reduced by 50% to 70%.5 At
doses >2 g/d of LA/SR niacin, mean transaminas-
es approached 3 times the upper limit of normal
(ULN), supporting recommendations not to exceed
this dose for LA/SR niacin.5
Several LA/SR products exist, and their differ-
ing pharmacologic and clinical properties necessi-
tate monitoring as though starting anew when
changing from one LA/SR formulation to another.1
Because of the unfavorable risk-benefit ratio of
LA/SR formulations compared with other niacin
formulations, production and marketing of many
Because LA/SR niacin has an active metabolite
(nicotinamide), hepatotoxicity is more likely to
occur with the LA/SR formulation than with IR
niacin.3 In a small prospective comparative study
of IR and LA/SR niacin (n=46), 0/23 patients tak-
ing IR niacin exhibited hepatic toxicity, compared
with 12/23 (52%) of patients taking the LA/SR
formulation.5 In this study, patients receiving 1 g/d
of LA/SR niacin had increases in transaminases
similar to those of patients on 3 g/d of IR niacin. It
is therefore recommended that if a patient cannot
tolerate IR niacin and is switched to the LA/SR
Studies of niacin toxicity
Pts/duration 
Author, evidence of Rx Lipid therapy Hepatotoxicity
Gray,2 retrospective 896 pts/ LA/SR (Slo-Niacin) 2.2% probable,
cohort 1–3 mos avg 1500 mg/d 4.7% possible or probable
Capuzzi,6 open-label, 517 pts/ ER (Niaspan) <1% w/ transaminases
prospective ≤96 wks 1000–3000 mg/d >3 times ULN
McKenney,5 randomized, 46 pts/ LA/SR niacin or IR niacin: 52% SR pts with  
double-blind, 30 wks titrated from 500 mg/d to transaminases (78% SR pts 
placebo-controlled 3000 mg/d withdrew); 0% IR pts with  
transaminases
Grundy,9 randomized, 97 pts/ ER (Niaspan) 0% with transaminases 
double-blind, 16 wks 1000–1500 mg/d >3 times ULN
placebo-controlled
Zhao,10 randomized, 80 pts/ LA/SR niacin (Slo-Niacin) 3% w/transaminases 
double-blind, 38 mos 250 mg twice daily titrated >3 times ULN (transient— 
placebo-controlled to 1000 mg twice daily or resolved with temporary halt 
switched to IR (Niacor) or decrease in med)
titrated to 3000–4000 mg/d 
+ simvastatin 10 mg/d 
titrated to maintain LDL-C
Parra,3 randomized, 74 pts/ IR niacin titrated to max of 3000 0% with transaminases 
double-blind 9 wks mg/d + fluvastatin 20 mg/d >3 times ULN
Davignon,11 randomized, 168 pts/ LA/SR niacin (Nicobid) 3% > 3 times baseline 
placebo-controlled 96 wks 1000 mg twice daily vs transaminases (Nicobid 
Nicobid 1000 mg twice alone) vs 1.2% >3 times
daily + pravastatin 40 mg baseline transaminases
nightly (Nicobid + pravastatin)
LA/SR, long-acting/sustained release; IR, immediate release; ER, extended release; ULN, upper limit of normal; 
LDL-C; low-density lipoprotein cholesterol.
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LA/SR niacin brands has ceased. The ER formu-
lation (Niaspan), only available by prescription,
has a balanced metabolism resulting in less 
hepatotoxicity (<1%).1,6 Expert opinion mandates
continued annual monitoring of liver function
tests (LFT) for all patients, including those on a
stable ER niacin dose, no new risk factors for
hepatotoxicity, and a series of normal LFTs.7
■ RECOMMENDATIONS FROM OTHERS
Elevated hepatic enzymes <3 times the ULN may
occur but usually resolve with continued therapy or
reduced doses. Enzymes >3 times the ULN require
discontinuation of therapy.8 The American Society
of Health-System Pharmacists (ASHP) recom-
mends screening at baseline, every 2 to 3 months
for the first year and every 6 to 12 months there-
after.8 The ASHP also recommends that patients be
started on IR niacin products, with consideration of
ER products only when IR products are not tolerat-
ed or alternative products are ineffective. ASHP
makes no mention of LA/SR products in their rec-
ommendations.8 They recommend more frequent
monitoring for high-risk patients—risks include
doses >2 g/d for LA/SR and >3 g/d for IR; LA/SR
formulations; switching between formulations; tak-
ing concomitant drugs that interact (ie, sulfony-
lureas); excessive alcohol use (undefined); and pre-
existing liver disease (based on a bivariate analysis
of factors associated with increased risk of hepatic
toxicity from a single retrospective cohort study)5—
and for patients who demonstrate signs/symptoms
of toxicity (nausea, vomiting, malaise, loss of
appetite, right upper quadrant pain, jaundice, and
dark urine).8 The National Cholesterol Education
Program Expert Panel update in 2004 recommend-
ed obtaining ALT/AST initially, 6 to 8 weeks after
reaching a daily dose of 1500 mg, 6 to 8 weeks after
reaching the maximum daily dose, then annually or
more frequently if indicated.7
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■ CLINICAL COMMENTARY
Risk of toxicity with long-acting niacin
is significant enough to avoid use
Our clinical experience is that once our
patients are on stable doses of most medicines
and have had a series of normal lab tests, we
are unlikely to find toxicities from continued
routine testing. That appears to be the case
with niacin and liver toxicity, but long-term
data are lacking for asymptomatic late reac-
tions to usual niacin doses. The risk of toxicity
with “long-acting” forms of niacin is significant
enough that I see no reason to use them at all.
If one wants to save money, use IR niacin. If
cost is not an issue or regular niacin is not 
tolerated, I use the ER Niaspan. Both of these
forms have very low rates of liver toxicity.
Louis Sanner, MD, University of Wisconsin Medical
School, Madison Family Practice Residency
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One of the largest and most recent of these
studies reports adjusted odds for development of
coronary artery disease of 1.45 (95% confidence
interval [CI], 1.25–1.68) for subjects in the top
third of hs-CRP levels compared with those in the
bottom third.9 Odds ratios (OR) for other predic-
tors of coronary artery disease are higher 
than this, in particular total cholesterol
(OR=2.35; 95% CI, 2.03–2.74), cigarette smok-
ing (OR=1.87; 95% CI, 1.62–2.22), and elevated
systolic blood pressure (OR=1.50; 95% CI,
1.30–1.73). This shows that hs-CRP does not
contribute as much as these factors to the estab-
lished risk profile for coronary heart disease.
These same authors go on to provide a 
systematic review of 22 prospective studies of 
hs-CRP involving 7068 patients, which showed
that an elevated hs-CRP was associated with
higher odds of developing coronary artery disease
(OR=1.58; 95% CI, 1.48–1.68). They also exam-
ined the largest 4 studies in their review (which
included 4107 cases) and found a slightly lower
OR of 1.49 (95% CI, 1.37–1.62). This meta-analy-
sis included only studies published since 2000
because earlier studies, which had yielded higher
odds for hs-CRP, suggested a pattern consistent
with publication bias. 
Two very recent studies evaluating statin ther-
apy for CVD suggest that CRP may be monitored
as an independent factor for predicting CVD out-
comes for patients undergoing aggressive lipid
therapy.10,11 These randomized, masked trials sug-
gest that CRP is directly predictive of recurrent
events among patients with known CVD. Its use-
fulness may be greatest when trying to decide
whether to pursue aggressive (high-dose) statin
therapy for these patients.
It is not clear whether hs-CRP is a direct,
causative marker for atherosclerosis or whether
it is simply a proxy marker elevated in conjunc-
tion with other known risk factors. This issue,
combined with the fact that its elevation does not 
contribute as significantly as other risk factors,
makes hs-CRP an inappropriate screening test
for cardiovascular disease in the healthy adult 
10. Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolera-
bility of simvastatin plus niacin in patients with coronary
artery disease and low high-density lipoprotein choles-
terol (The HDL Atherosclerosis Treatment Study). 
Am J Cardiol 2004; 93:307–312.
11. Davignon J, Roederer G, Montigny M, et al. Comparative
efficacy and safety of pravastatin, nicotinic acid and the
two combined in patients with hypercholesterolemia. 
Am J Cardiol 1994; 73:339–345.
How useful is high-sensitivity
CRP as a risk factor 
for coronary artery disease?
■ EVIDENCE-BASED ANSWER
Little evidence supports the use of the high-sen-
sitivity C-reactive protein assay (hs-CRP) as a
screening test for cardiovascular disease (CVD)
in the healthy adult population. There is signifi-
cant debate about its use in populations at mod-
erate risk for cardiovascular disease, with some
evidence suggesting its use if the results of the
test will alter treatment recommendations1
(strength of recommendation [SOR]: C, based on
extrapolation of consistent level 2 studies).
Research to date is inadequate to determine the
role of hs-CRP in risk-stratification of patients
when considered in light of other standard risk
factors (Table).
■ EVIDENCE SUMMARY
C-reactive protein is a nonspecific serum marker
of inflammatory response. While it is elevated in
a variety of conditions, a link has been suggested
between CRP and pathogenesis of clinical cardio-
vascular disease.1
Several retrospective studies have reported
risk ratios for developing cardiovascular disease,
ranging from 2.3 to 4.4 when comparing subjects
with the highest levels of hs-CRP with those who
have the lowest levels.2–9 Though systematic bias
in retrospective study design limits the interpreta-
tion of these findings, the findings are of some
benefit to answering this question when large,
prospective, randomized studies are not available. 
